The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Editorial Comment
Ethosuximide in childhood absence epilepsy--older and better.
-
Randomized Controlled Trial Multicenter Study
Lasofoxifene in postmenopausal women with osteoporosis.
The effects of lasofoxifene on the risk of fractures, breast cancer, and cardiovascular disease are uncertain. ⋯ In postmenopausal women with osteoporosis, lasofoxifene at a dose of 0.5 mg per day was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. (ClinicalTrials.gov number, NCT00141323.)